Thoracic aortic aneurysm epidemiology and demographics

Thoracic aortic aneurysm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thoracic Aortic Aneurysm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
General Approach to Imaging in Thoracic Aortic Aneurysm
Chest X Ray
MRI
CT
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Endovascular Stent Grafting
Lifestyle Changes
Special Scenarios
Management during Pregnancy
Case Studies
Case #1
Thoracic aortic aneurysm epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thoracic aortic aneurysm epidemiology and demographics
CDC on Thoracic aortic aneurysm epidemiology and demographics
Thoracic aortic aneurysm epidemiology and demographics in the news
Blogs on Thoracic aortic aneurysm epidemiology and demographics
Directions to Hospitals Treating Thoracic aortic aneurysm epidemiology and demographics
Risk calculators and risk factors for Thoracic aortic aneurysm epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Editor-in-Chief: Amjad AlMahameed, MD, MPH, RPVI, FACP. Beth Israel Deaconess Medical Center and Harvard Medical School. Boston, USA

Epidemiology and Demographics

TAAs are relatively uncommon with an estimated incidence between 6 and 10 new aneurysms per 100,000 person-years. TAAs are usually diagnosed after the sixth decade of life and they typically expand slowly (approximately 0.1-0.2 cm/year). The risk of rupture is closely related to aneurysm size (3% for TAAs <4 cm and 7% for >6 cm). These bioepidemiological characteristics support the current stand that screening for TAA is not recommended in the general population. Certain population substrates, such as those with history of Marfan's syndrome, Turner's syndrome, Ehlers-Danlos type IV syndrome, familial thoracic aortic disease syndromes, and patients with bicuspid aortic valve should have imaging study to screen for TAAs.